Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome

Abstract

Marfan syndrome is an autosomal dominant disorder of connective tissue caused by mutations in fibrillin-1 (encoded by FBN1 in humans and Fbn1 in mice), a matrix component of extracellular microfibrils. A distinct subgroup of individuals with Marfan syndrome have distal airspace enlargement, historically described as emphysema, which frequently results in spontaneous lung rupture (pneumothorax; refs. 13). To investigate the pathogenesis of genetically imposed emphysema, we analyzed the lung phenotype of mice deficient in fibrillin-1, an accepted model of Marfan syndrome4. Lung abnormalities are evident in the immediate postnatal period and manifest as a developmental impairment of distal alveolar septation. Aged mice deficient in fibrillin-1 develop destructive emphysema consistent with the view that early developmental perturbations can predispose to late-onset, seemingly acquired phenotypes. We show that mice deficient in fibrillin-1 have marked dysregulation of transforming growth factor-β (TGF-β) activation and signaling, resulting in apoptosis in the developing lung. Perinatal antagonism of TGF-β attenuates apoptosis and rescues alveolar septation in vivo. These data indicate that matrix sequestration of cytokines is crucial to their regulated activation and signaling and that perturbation of this function can contribute to the pathogenesis of disease.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Lung histopathology and morphometry of mice deficient in fibrillin-1.
Figure 2: Cell differentiation and elastin deposition in the lungs of mice deficient in fibrillin-1.
Figure 3: Active TGF-β expression and signaling in lung tissue of mice deficient in fibrillin-1.
Figure 4: Neutralizing antibody to TGF-β rescues lung maturation in mice deficient in fibrillin-1.
Figure 5: Mice deficient in fibrillin-1 have preserved lung cell proliferation but greater apoptosis.
Figure 6: Lung phenotype of wild-type (+/+) and Fbn1mgR/mgR (−/−) mice.

Similar content being viewed by others

References

  1. Dwyer, E.M. & Troncale, F. Spontaneous pneumothorax and pulmonary disease in the Marfan syndrome. Ann. Intern. Med. 62, 1285–1292 (1965).

    Article  Google Scholar 

  2. Hall, J.R., Pyeritz, R.E., Dudgeon, D.L. & Haller, J.A., Jr. Pneumothorax in the Marfan syndrome: prevalence and therapy. Ann. Thorac. Surg. 37, 500–504 (1984).

    Article  CAS  Google Scholar 

  3. Wood, J.R., Bellamy, D., Child, A.H. & Citron, K.M. Pulmonary disease in patients with Marfan syndrome. Thorax 39, 780–784 (1984).

    Article  CAS  Google Scholar 

  4. Pereira, L. et al. Targetting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome. Nat. Genet. 17, 218–222 (1997).

    Article  CAS  Google Scholar 

  5. Thurlbeck, W.M. Measurement of pulmonary emphysema. Am. Rev. Respir. Dis. 95, 752–764 (1967).

    CAS  PubMed  Google Scholar 

  6. Zhou, L., Lim, L., Costa, R.H. & Whitsett, J.A. Thyroid transcription factor-1, hepatocyte nuclear factor-3beta, surfactant protein B, C, and Clara cell secretory protein in developing mouse lung. J Histochem. Cytochem. 44, 1183–1193 (1996).

    Article  CAS  Google Scholar 

  7. Bostrom, H. et al. PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis. Cell 85, 863–873 (1996).

    Article  CAS  Google Scholar 

  8. Nakamura, T. et al. Fibulin-5/DANCE is essential for elastogenesis in vivo. Nature 415, 171–175 (2002).

    Article  CAS  Google Scholar 

  9. Weinstein, M., Xu, X., Ohyama, K. & Deng, C.X. FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung. Development 125, 3615–3623 (1998).

    CAS  Google Scholar 

  10. Wendel, D.P., Taylor, D.G., Albertine, K.H., Keating, M.T. & Li, D.Y. Impaired distal airway development in mice lacking elastin. Am. J. Respir. Cell Mol. Biol. 23, 320–326 (2000).

    Article  CAS  Google Scholar 

  11. Taipale, J., Saharinen, J., Hedman, K. & Keski-Oja, J. Latent transforming growth factor-β 1 and its binding protein are components of extracellular matrix microfibrils. J. Histochem. Cytochem. 44, 875–889 (1996).

    Article  CAS  Google Scholar 

  12. Unsold, C., Hyytiainen, M., Bruckner-Tuderman, L. & Keski-Oja, J. Latent TGF-β binding protein LTBP-1 contains three potential extracellular matrix interacting domains. J. Cell. Sci. 114, 187–197 (2001).

    CAS  PubMed  Google Scholar 

  13. Dallas, S.L., Miyazono, K., Skerry, T.M., Mundy, G.R. & Bonewald, L.F. Dual role for the latent transforming growth factor-β binding protein in storage of latent TGF-β in the extracellular matrix and as a structural matrix protein. J. Cell Biol. 131, 539–549 (1995).

    Article  CAS  Google Scholar 

  14. Dallas, S.L. et al. Role of the latent transforming growth factor-β binding protein 1 in fibrillin-containing microfibrils in bone cells in vitro and in vivo. J. Bone Miner. Res. 15, 68–81 (2000).

    Article  CAS  Google Scholar 

  15. Isogai, Z. et al. Latent transforming growth factor-β binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J. Biol. Chem. 278, 2750–2757 (2003).

    Article  CAS  Google Scholar 

  16. Barcellos-Hoff, M.H. et al. Immunohistochemical detection of active transforming growth factor-β in situ using engineered tissue. Am. J. Pathol. 147, 1228–1237 (1995).

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Flanders, K.C. et al. Transforming growth factor-β 1: histochemical localization with antibodies to different epitopes. J. Cell Biol. 108, 653–660 (1989).

    Article  CAS  Google Scholar 

  18. Dennler, S. et al. Direct binding of Smad3 and Smad4 to critical TGFβ-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 17, 3091–3100 (1998).

    Article  CAS  Google Scholar 

  19. Tomita, H. et al. Early induction of transforming growth factor-β via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 32, 273–279 (1998).

    Article  CAS  Google Scholar 

  20. Yamamoto, T., Takagawa, S., Katayama, I. & Nishioka, K. Anti-sclerotic effect of transforming growth factor-β antibody in a mouse model of bleomycin-induced scleroderma. Clin. Immunol. 92, 6–13 (1999).

    Article  CAS  Google Scholar 

  21. Moustakas, A., Pardali, K., Gaal, A. & Heldin, C.H. Mechanisms of TGF-β signaling in regulation of cell growth and differentiation. Immunol. Lett. 82, 85–91 (2002).

    Article  CAS  Google Scholar 

  22. Pereira, L. et al. Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1. Proc. Natl. Acad. Sci. USA 96, 3819–3823 (1999).

    Article  CAS  Google Scholar 

  23. Bunton, T.E. et al. Phenotypic alteration of vascular smooth muscle cells precedes elastolysis in a mouse model of Marfan syndrome. Circ. Res. 88, 37–43 (2001).

    Article  CAS  Google Scholar 

  24. Nijbroek, G. et al. Fifteen novel FBN1 mutations causing Marfan syndrome detected by heteroduplex analysis of genomic amplicons. Am. J. Hum. Genet. 57, 8–21 (1995).

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank J. Gauthier for providing reagents, D. Valle for helpful comments about the manuscript, M. Barcellos-Hoffs for advice about the use of TGF-β antibodies, M. Dellanoy for help with confocal imaging and members of H.C.D.'s laboratory for their support and advice. This work was supported by Robert Wood Johnson Foundation (to E.R.N.), Howard Hughes Medical Institute (to H.C.D.), US National Institutes of Health grants (to E.R.N., H.C.D. and F.R.), the Michael Murray fund from the National Marfan Foundation (to H.C.D.), Smilow Foundation (to H.C.D.) and Dr. Amy and James Elster Research Fund (to F.R.).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Harry C. Dietz.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neptune, E., Frischmeyer, P., Arking, D. et al. Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome. Nat Genet 33, 407–411 (2003). https://doi.org/10.1038/ng1116

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ng1116

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing